Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Compound K Mitigates PM <sub>2.5</sub>-induced Premature Senescence in ARPE-19 Human Retinal Pigment Epithelial Cells through Activation of the Nrf2/HO-1 Pathway.

Biomedical and environmental sciences : BES·2026

Same author

Histamine-Mediated Syndrome (HMS): Beyond Allergy and Therapeutic Potential of Immunoglobulin/Histamine Complex (IHC).

International journal of molecular sciences·2026

Same author

Nociceptive pain as a clinical presentation of chronic urticaria and disappearance with immunoglobulin/histamine complex therapy: a case report.

Ewha medical journal·2026

Same author

Pluviatolide Attenuates Type I Hypersensitivity through Regulation of Mast Cell Activation.

Biomolecules & therapeutics·2026

Same author

Erratum to "Morroniside Protects C2C12 Myoblasts from Oxidative Damage Caused by ROS-mediated Mitochondrial Damage and Induction of Endoplasmic Reticulum Stress" [Biomol Ther 32(3), 349-360 (2024)].

Biomolecules & therapeutics·2025

Same author

The impact of atmospheric ultrafine particulate matter on IgE-mediated type 1 hypersensitivity reaction.

Journal of hazardous materials·2024

Search research articles

Related Experiment Video

Updated: Sep 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Immunotherapy using Histobulin™ in psoriasis: A case report.

Hyuk Soon Kim¹, Geunwoong Noh²

¹Department of Biomedical Sciences College of Natural Science and Department of Health Sciences The Graduate School of Dong-A University Busan Korea.

Clinical Case Reports

|May 20, 2022

Summary

This summary is machine-generated.

Histobulin™ shows promise as a curative therapy for psoriasis, effectively clearing patient symptoms for over 18 months. This novel treatment offers hope for long-term psoriasis remission.

Keywords:

Histobulin™biologics immunoglobulin/histamine complex immunotherapy psoriasis

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Experiment Videos

Last Updated: Sep 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

Dermatology
Immunology
Pharmacology

Background:

Psoriasis is a chronic autoimmune condition with no current cure.
Existing treatments aim to manage symptoms and inflammation.

Observation:

A single patient with psoriasis was administered Histobulin™.
Treatment involved multiple injections over a period of time.

Findings:

Complete resolution of clinical psoriasis symptoms and signs was observed after eight injections.
Symptomatic relief persisted for over 18 months post-treatment, indicating sustained efficacy.
Histobulin™ demonstrated significant therapeutic effectiveness in this psoriasis case.

Implications:

Histobulin™ presents a potential curative therapeutic option for psoriasis.
Further clinical trials are warranted to validate these findings in a larger patient cohort.
This research could lead to a breakthrough in psoriasis management and treatment paradigms.